Indonesia Pharma and Healthcare Sector Report 2023-2024

Indonesia's pharmaceuticals and healthcare sector is amongst the fastest growing in the ASEAN region. The Indonesian government introduced a comprehensive public health insurance programme in 2014 to deliver universal healthcare to Indonesians. The progressive rollout of this programme has allowed more Indonesians to afford modern healthcare services, motivating healthcare providers to build additional capacity to cater for the increased demand. The healthcare system is highly dependent on imported medical devices and pharmaceuticals due to the inability of domestic producers to manufacture many of the critical supplies needed by hospitals and clinics. The Indonesian government has recently introduced policies to liberalise the investment environment, hoping to encourage foreign companies to establish their production facilities in Indonesia, thereby reducing import dependence.

This report provides a complete and detailed analysis of the "Healthcare and pharma" sector for Indonesia. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Healthcare and pharma" sector in Indonesia
• Crystallise the forces both driving and restraining this sector in Indonesia
• Ascertain Indonesia’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Indonesia.
• Build a clear picture of trends, output and consumption for specific sub-sectors